Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Lexeo Therapeutics reports an 80% mean arrhythmia reduction in its Phase 1/2 LX2020 heart trial and targets a pivotal trial in late 2027.
Follow the latest Lexeo Therapeutics, Inc. (LXEO) news and market headlines alongside the live LXEO price. Stay informed on what's moving LXEO.
Lexeo Therapeutics reports an 80% mean arrhythmia reduction in its Phase 1/2 LX2020 heart trial and targets a pivotal trial in late 2027.
Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.
Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.33) by 30.3 percent. This is a 30.3 percent decrease over losses of $(0.33) per share
Lexeo Therapeutics announced it will report Q3 2026 financial results and provide a business update on the HEROIC-PKP2 Phase I/II clinical trial of LX2020, an AAV-based gene therapy for PKP2 arrhythmogenic cardiomyopathy, on November 16, 2026. The company is advancing a portfolio of therapeutic candidates for cardiovascular and neurological genetic diseases with high unmet need.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to LXEO, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.